Regenerx Biopharmaceuticals Inc (RGRX)
0.0014
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Regenerx Biopharmaceuticals Net Income (Quarterly): -0.3852M for March 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2023 | -0.3852M |
| December 31, 2022 | -0.3909M |
| September 30, 2022 | -0.3665M |
| June 30, 2022 | -0.546M |
| March 31, 2022 | -0.4241M |
| December 31, 2021 | -0.4496M |
| September 30, 2021 | -0.4298M |
| June 30, 2021 | -0.3386M |
| March 31, 2021 | -0.3797M |
| December 31, 2020 | -0.3679M |
| September 30, 2020 | -0.3326M |
| June 30, 2020 | -0.4362M |
| March 31, 2020 | -0.3867M |
| December 31, 2019 | -0.3494M |
| September 30, 2019 | -0.3339M |
| June 30, 2019 | -0.3884M |
| March 31, 2019 | -0.3325M |
| December 31, 2018 | -0.2638M |
| September 30, 2018 | -0.376M |
| June 30, 2018 | -0.3679M |
| March 31, 2018 | -0.9859M |
| December 31, 2017 | 1.417M |
| September 30, 2017 | -1.359M |
| June 30, 2017 | 0.1184M |
| March 31, 2017 | 0.1093M |
| Date | Value |
|---|---|
| December 31, 2016 | 0.4221M |
| September 30, 2016 | 0.8617M |
| June 30, 2016 | 2.324M |
| March 31, 2016 | -3.379M |
| December 31, 2015 | -0.6602M |
| September 30, 2015 | -1.130M |
| June 30, 2015 | -1.762M |
| March 31, 2015 | -1.719M |
| December 31, 2014 | -0.5332M |
| September 30, 2014 | 0.1234M |
| June 30, 2014 | -0.2188M |
| March 31, 2014 | -2.125M |
| December 31, 2013 | -0.0089M |
| September 30, 2013 | -0.0998M |
| June 30, 2013 | -0.2302M |
| March 31, 2013 | -0.3324M |
| December 31, 2012 | -0.0979M |
| September 30, 2012 | -0.0945M |
| June 30, 2012 | -0.2257M |
| March 31, 2012 | -0.429M |
| December 31, 2011 | -0.8607M |
| September 30, 2011 | -2.018M |
| June 30, 2011 | -1.532M |
| March 31, 2011 | -1.596M |
| December 31, 2010 | -0.9199M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-0.546M
Minimum
Jun 2022
-0.3326M
Maximum
Sep 2020
-0.3988M
Average
-0.386M
Median
Net Income (Quarterly) Benchmarks
| Ampio Pharmaceuticals Inc | -2.054M |
| FluoroPharma Medical Inc | -0.1272M |
| Evolutionary Genomics Inc | -0.3338M |
| Xeno Transplants Corp | -- |
| Entia Biosciences Inc | -0.4328M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.0192M |
| Total Expenses (Quarterly) | 0.3241M |
| EPS Diluted (Quarterly) | -0.2683 |